Medtronic Completes Purchase of QT Vascular's Chocolate PTA Balloon Catheter


January 29, 2018—QT Vascular Ltd. announced completion of the sale of the company's Chocolate percutaneous transluminal angioplasty balloon catheter to Medtronic for $28 million.

In the United States, the Chocolate PTA balloon catheter is intended for balloon dilatation of lesions in the peripheral vasculature, including the iliac, femoral, iliofemoral, popliteal, infrapopliteal, and renal arteries. It is currently commercially available from Medtronic in the United States and Europe.

In May 2017, QT Vascular announced an asset purchase option agreement with Medtronic for the acquisition of the Chocolate PTA catheter, which would be exercisable upon achievement of certain milestones. In February 2017, the company announced a definitive agreement with Medtronic for the worldwide distribution of the Chocolate PTA catheter for a 5-year period and automatically renewable for two additional 1-year periods.

QT Vascular will independently continue to develop and market its other products including the Chocolate Touch (a drug-coated version of the Chocolate PTA device), which has received investigational device exemption approval from the US Food and Drug Administration, as well as its coronary product portfolio of both drug-coated and non–drug-coated products.


Contact Info

For advertising rates and opportunities, contact:
Craig McChesney

Stephen Hoerst

Charles Philip

About Endovascular Today

Endovascular Today is a publication dedicated to bringing you comprehensive coverage of all the latest technology, techniques, and developments in the endovascular field. Our Editorial Advisory Board is composed of the top endovascular specialists, including interventional cardiologists, interventional radiologists, vascular surgeons, neurologists, and vascular medicine practitioners, and our publication is read by an audience of more than 22,000 members of the endovascular community.